Details for Patent: 8,945,516

✉ Email this page to a colleague

Which drugs does patent 8,945,516 protect, and when does it expire?

Patent 8,945,516 protects AMZEEQ and ZILXI and is included in two NDAs.

This patent has twenty-two patent family members in ten countries.

Summary for Patent: 8,945,516

Title:	Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Abstract:	A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent free composition.
Inventor(s):	Tamarkin; Dov (Ness Ziona, IL), Gazal; Elana (Rehovot, IL), Papiashvili; Irakliy (Askelon, IL), Hazot; Yohan (Rehovot, IL), Schuz; David (Moshav, IL), Keynan; Rita (Rehovot, IL)
Assignee:	Foamix Pharmaceuticals Ltd. (Rehovot, IL)
Application Number:	13/499,501
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,945,516
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 8,945,516

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Journey	AMZEEQ	minocycline hydrochloride	AEROSOL, FOAM;TOPICAL	212379-001	Oct 18, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Journey	ZILXI	minocycline hydrochloride	AEROSOL, FOAM;TOPICAL	213690-001	May 28, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,945,516

PCT Information
PCT Filed	October 01, 2010	PCT Application Number:	PCT/IB2010/002612
PCT Publication Date:	April 07, 2011	PCT Publication Number:	WO2011/039637

International Family Members for US Patent 8,945,516

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010302350	⤷ Sign Up
Australia	2015224534	⤷ Sign Up
Brazil	112012007473	⤷ Sign Up
Canada	2776366	⤷ Sign Up
Canada	2776471	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.